Search

Your search keyword '"Kloza M"' showing total 16 results
Start Over Author "Kloza M" Publication Year Range Last 10 years
16 results on '"Kloza M"'

1. NITRIC OXIDE AS AMODULATOR IN PLATELET- AND ENDOTHELIUM-DEPENDENT ANTITHROMBOTIC EFFECT OF EPLERENONE IN DIABETIC RATS.

Author

GROMOTOWICZ-POPLAWSKA, A., KLOZA, M., ALEKSIEJCZUK, M., MARCINCZYK, N., SZEMRAJ, J., KOZLOWSKA, H., and CHABIELSKA, E.

Subjects
NITRIC oxide, NITRIC-oxide synthases, FIBRINOLYTIC agents, ENDOTHELIUM, BLOOD platelets, PHARMACODYNAMICS, DIABETES, THROMBOSIS
Abstract

We have recently demonstrated the antithrombotic effect of eplerenone on the arterial thrombotic process in diabetic rats associated with suppression of coagulation and enhancement of fibrinolysis. The aim of this study was to evaluate the role of platelets and endothelium in the mechanism of eplerenone antithrombotic action. Diabetes was induced in male Wistar rats with a single injection of streptozotocin (65 mg/kg). On the 25th day, treatment with eplerenone (100 mg/kg) was initiated for 10 days. Eplerenone did not change hemodynamic parameters (blood pressure, carotid blood flow, and heart rate), however, improved endothelium-dependent vasorelaxation in aortas and small mesenteric arteries, enhanced the aortic amounts of mRNA of endothelial nitric oxide synthase (eNOS), and reduced mRNA of nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) oxidase 2. A prolongation of bleeding time and decrease in platelet adhesion to collagen ex vivo was also observed. These changes were accompanied by prolonged time to occlusion and increased blood flow, and finally reduced thrombus mass in diabetic rats. The inhibition of NOS with L-NAME reduced the eplerenone antithrombotic effect. Our study provides evidence that the antithrombotic effect of eplerenone in diabetic rats is nitric oxide-dependent and associated with inhibiting the adhesion of platelets, as well as normalizing endothelial function. The mechanism of eplerenone antithrombotic action in diabetes is a result of improved endothelial nitric oxide bioavailability that leads to the improvement vascular and platelet function. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

2. Poster session 3Cell growth, differentiation and stem cells - Heart511The role of the endocannabinoid system in modelling muscular dystrophy cardiac disease with induced pluripotent stem cells.512An emerging role of T lymphocytes in cardiac regenerative processes in heart failure due to dilated cardiomyopathy513Canonical wnt signaling reverses the ‘aged/senescent’ human endogenous cardiac stem cell phenotype514Hippo signalling modulates survival of human induced pluripotent stem cell-derived cardiomyocytes515Biocompatibility of mesenchymal stem cells with a spider silk matrix and its potential use as scaffold for cardiac tissue regeneration516A snapshot of genome-wide transcription in human induced pluripotent stem cell-derived hepatocyte-like cells (iPSC-HLCs)517Can NOS/sGC/cGK1 pathway trigger the differentiation and maturation of mouse embryonic stem cells (ESCs)?518Introduction of external Ik1 to human-induced pluripotent stem cell-derived cardiomyocytes via Ik1-expressing HEK293519Cell therapy of the heart studied using adult myocardial slices in vitro520Enhancement of the paracrine potential of human adipose derived stem cells when cultured as spheroid bodies521Mechanosensitivity of cardiomyocyte progenitor cells: the strain response in 2D and 3D environments522The effect of the vascular-like network on the maturation of the human induced pluripotent stem cell derived cardiomyocytes.Transcriptional control and RNA species - Heart525Gene expression regulation in heart failure: from pathobiology to bioinformatics526Human transcriptome in idiopathic dilated cardiomyopathy - a novel high throughput screening527A high-throghput approach unveils putative miRNA-mediated mitochondria-targeted cardioprotective circuits activated by T3 in the post ischemia reperfusion setting528The effect of uraemia on the expression of miR-212/132 and the calcineurin pathway in the rat heartCytokines and cellular inflammation - Heart531Lack of growth differentiation factor 15 aggravates adverse cardiac remodeling upon pressure-overload in mice532Blocking heteromerization of platelet chemokines ccl5 and cxcl4 reduces inflammation and preserves heart function after myocardial infarction533Is there an association between low-dose aspirin use and clinical outcome in HFPEF? Implications of modulating monocyte function and inflammatory mediator release534N-terminal truncated intracellular matrix metalloproteinase-2 expression in diabetic heart.535Expression of CD39 and CD73 on peripheral T-cell subsets in calcific aortic stenosis536Mast cells in the atrial myocardium of patients with atrial fibrillation: a comparison with patients in sinus rhythm539Characteristics of the inflammatory response in patients with coronary artery disease and arterial hypertension540Pro-inflammatory cytokines as cardiovascular events predictors in rheumatoid arthritis and asymptomatic atherosclerosis541Characterization of FVB/N murinic bone marrow-derived macrophage polarization into M1 and M2 phenotypes542The biological expression and thoracic anterior pain syndromeSignal transduction - Heart545The association of heat shock protein 90 and TGFbeta receptor I is involved in collagen production during cardiac remodelling in aortic-banded mice546Loss of the inhibitory GalphaO protein in the rostral ventrolateral medulla of the brainstem leads to abnormalities in cardiovascular reflexes and altered ventricular excitablitiy547Selenoprotein P regulates pressure overload-induced cardiac remodeling548Study of adenylyl cyclase activity in erythrocyte membranes in patients with chronic heart failure549Direct thrombin inhibitors inhibit atrial myocardium hypertrophy in a rat model of heart failure and atrial remodeling550Tissue factor / FVIIa transactivates the IGF-1R by a Src-dependent phosphorylation of caveolin-1551Notch signaling is differently altered in endothelial and smooth muscle cells of ascending aortic aneurysm patients552Frizzled 5 expression is essential for endothelial proliferation and migration553Modulation of vascular function and ROS production by novel synthetic benzopyran analogues in diabetes mellitusExtracellular matrix and fibrosis - Heart556Cardiac fibroblasts as inflammatory supporter cells trigger cardiac inflammation in heart failure557A role for galectin-3 in calcific aortic valve stenosis558Omega-3 polyunsaturated fatty acids- can they decrease risk for ventricular fibrillation?559Serum levels of elastin derived peptides and circulating elastin-antielastin immune complexes in sera of patients with coronary artery disease560Endocardial fibroelastosis is secondary to hemodynamic alterations in the chick model of hypoplastic left heart syndrome561Dynamics of serum levels of matrix metalloproteinases in primary anterior STEMI patients564Deletion of the alpha-7 nicotinic acetylcholine receptor changes the vascular remodeling induced by transverse aortic constriction in mice.565Extracellular matrix remodelling in response to venous hypertension: proteomics of human varicose veinsIon channels, ion exchangers and cellular electrophysiology - Heart568Microtubule-associated protein RP/EB family member 1 modulates sodium channel trafficking and cardiac conduction569Investigation of electrophysiological abnormalities in a rabbit athlete's heart model570Upregulation of expression of multiple genes in the atrioventricular node of streptozotocin-induced diabetic rat571miR-1 as a regulator of sinoatrial rhythm in endurance training adaptation572Selective sodium-calcium exchanger inhibition reduces myocardial dysfunction associated with hypokalaemia and ventricular fibrillation573Effect of racemic and levo-methadone on action potential of human ventricular cardiomyocytes574Acute temperature effects on the chick embryonic heart functionVasculogenesis, angiogenesis and arteriogenesis577Clinical improvement and enhanced collateral vessel growth after monocyte transplantation in mice578The role of HIF-1 alpha, VEGF and obstructive sleep apnoea in the development of coronary collateral circulation579Initiating cardiac repair with a trans-coronary sinus catheter intervention in an ischemia/reperfusion porcine animal model580Early adaptation of pre-existing collaterals after acute arteriolar and venular microocclusion: an in vivo study in chick chorioallantoic membraneEndothelium583EDH-type responses to the activator of potassium KCa2.3 and KCa3.1 channels SKA-31 in the small mesenteric artery from spontaneously hypertensive rats584The peculiarities of endothelial dysfunction in patients with chronic renocardial syndrome585Endothelial dysfunction, atherosclerosis of the carotid arteries and level of leptin in patient with coronary heart disease in combination with hepatic steatosis depend from body mass index.586Role of non-coding RNAs in thoracic aortic aneurysm associated with bicuspid aortic valve587Cigarette smoke extract abrogates atheroprotective effects of high laminar flow on endothelial function588The prognostic value of anti-connective tissue antibodies in coronary heart disease and asymptomatic atherosclerosis589Novel potential properties of bioactive peptides from spanish dry-cured ham on the endothelium.Lipids592Intermediate density lipoprotein is associated with monocyte subset distribution in patients with stable atherosclerosis593The characteristics of dyslipidemia in rheumatoid arthritisAtherosclerosis596Macrophages differentiated in vitro are heterogeneous: morphological and functional profile in patients with coronary artery disease597Palmitoylethanolamide promotes anti-inflammatory phenotype of macrophages and attenuates plaque formation in ApoE-/- mice598Amiodarone versus esmolol in the perioperative period: an in vitro study of coronary artery bypass grafts599BMPRII signaling of fibrocytes, a mesenchymal progenitor cell population, is increased in STEMI and dyslipidemia600The characteristics of atherogenesis and systemic inflammation in rheumatoid arthritis601Role of adenosine-to-inosine RNA editing in human atherosclerosis602Presence of bacterial DNA in thrombus aspirates of patients with myocardial infarction603Novel E-selectin binding polymers reduce atherosclerotic lesions in ApoE(-/-) mice604Differential expression of the plasminogen receptor Plg-RKT in monocyte and macrophage subsets - possible functional consequences in atherogenesis605Apelin-13 treatment enhances the stability of atherosclerotic plaques606Mast cells are increased in the media of coronary lesions in patients with myocardial infarction and favor atherosclerotic plaque instability607Association of neutrophil to lymphocyte ratio with presence of isolated coronary artery ectasiaCalcium fluxes and excitation-contraction coupling610The coxsackie- and adenovirus receptor (CAR) regulates calcium homeostasis in the developing heart611HMW-AGEs application acutely reduces ICaL in adult cardiomyocytes612Measuring electrical conductibility of cardiac T-tubular systems613Postnatal development of cardiac excitation-contraction coupling in rats614Role of altered Ca2+ homeostasis during adverse cardiac remodeling after ischemia/reperfusion615Experimental study of sarcoplasmic reticulum dysfunction and energetic metabolism in failing myocardium associated with diabetes mellitusHibernation, stunning and preconditioning618Volatile anesthetic preconditioning attenuates ischemic-reperfusion injury in type II diabetic patients undergoing on-pump heart surgery619The effect of early and delayed phase of remote ischemic preconditioning on ischemia-reperfusion injury in the isolated hearts of healthy and diabetic rats620Post-conditioning with 1668-thioate leads to attenuation of the inflammatory response and remodeling with less fibrosis and better left ventricular function in a murine model of myocardial infarction621Maturation-related changes in response to ischemia-reperfusion injury and in effects of classical ischemic preconditioning and remote preconditioningMitochondria and energetics624Phase changes in myocardial mitochondrial respiration caused by hypoxic preconditioning or periodic hypoxic training625Desmin mutations depress mitochondrial metabolism626Methylene blue modulates mitochondrial function and monoamine oxidases-related ROS production in diabetic rat hearts627Doxorubicin modulates the real-time oxygen consumption rate of freshly isolated adult rat and human ventricular cardiomyocytesCardiomyopathies and fibrosis630Effects of genetic or pharmacologic inhibition of the ubiquitin/proteasome system on myocardial proteostasis and cardiac function631Suppression of Wnt signalling in a desmoglein-2 transgenic mouse model for arrhythmogenic cardiomyopathy632Cold-induced cardiac hypertrophy is reversed after thermo-neutral deacclimatization633CD45 is a sensitive marker to diagnose lymphocytic myocarditis in endomyocardial biopsies of living patients and in autopsies634Atrial epicardial adipose tissue derives from epicardial progenitors635Caloric restriction ameliorates cardiac function, sympathetic cardiac innervation and beta-adrenergic receptor signaling in an experimental model of post-ischemic heart failure636High fat diet improves cardiac remodelling and function after extensive myocardial infarction in mice637Epigenetic therapy reduces cardiac hypertrophy in murine models of heart failure638Imbalance of the VHL/HIF signaling in WT1+ Epicardial Progenitors results in coronary vascular defects, fibrosis and cardiac hypertrophy639Diastolic dysfunction is the first stage of the developing heart failure640Colchicine aggravates coxsackievirus B3 infection in miceArterial and pulmonary hypertension642Osteopontin as a marker of pulmonary hypertension in patients with coronary heart disease combined with chronic obstructive pulmonary disease643Myocardial dynamic stiffness is increased in experimental pulmonary hypertension partly due to incomplete relaxation644Hypotensive effect of quercetin is possibly mediated by down-regulation of immunotroteasome subunits in aorta of spontaneously hypertensive rats645Urocortin-2 improves right ventricular function and attenuates experimental pulmonary arterial hypertension646A preclinical evaluation of the anti-hypertensive properties of an aqueous extract of Agathosma (Buchu)Biomarkers648The adiponectin level in hypertensive females with rheumatoid arthritis and its relationship with subclinical atherosclerosis649Markers for identification of renal dysfunction in the patients with chronic heart failure650cardio-hepatic syndromes in chronic heart failure: North Africa profile651To study other biomarkers that assess during myocardial infarction652Interconnections of apelin levels with parameters of lipid metabolism in hypertension patients653Plasma proteomics in hypertension: prediction and follow-up of albuminuria during chronic renin-angiotensin system suppression654Soluble RAGE levels in plasma of patients with cerebrovascular events

Author

Gowran, A, primary, Kulikova, T, primary, Lewis, FC, primary, Foldes, G, primary, Fuentes, L, primary, Viiri, LE, primary, Spinelli, V, primary, Costa, A, primary, Perbellini, F, primary, Sid-Otmane, C, primary, Bax, NAM, primary, Pekkanen-Mattila, M, primary, Schiano, C, primary, Chaloupka, A, primary, Forini, F, primary, Sarkozy, M, primary, De Jager, SCA, primary, Vajen, T, primary, Glezeva, N, primary, Lee, H W, primary, Golovkin, A, primary, Kucera, T, primary, Musikhina, NA, primary, Korzhenkov, NP, primary, Santuchi, M DE C, primary, Munteanu, D, primary, Garcia, RG, primary, Ang, R, primary, Usui, S, primary, Kamilova, U, primary, Jumeau, C, primary, Aberg, M, primary, Kostina, DA, primary, Brandt, MM, primary, Muntean, D, primary, Lindner, D, primary, Sadaba, R, primary, Bacova, B, primary, Nikolov, A, primary, Sedmera, D, primary, Ryabov, V, primary, Neto, FP, primary, Lynch, M, primary, Portero, V, primary, Kui, P, primary, Howarth, FC, primary, Gualdoni, A, primary, Prorok, J, primary, Diolaiuti, L, primary, Vostarek, F, primary, Wagner, M, primary, Abela, MA, primary, Nebert, C, primary, Xiang, W, primary, Kloza, M, primary, Maslenko, A, primary, Grechanyk, M, primary, Bhattachariya, A, primary, Morawietz, H, primary, Babaeva, AR, primary, Martinez Sanchez, SM, primary, Krychtiuk, KA, primary, Starodubova, J, primary, Fiorelli, S, primary, Rinne, P, primary, Ozkaramanli Gur, D, primary, Hofbauer, T, primary, Stellos, K, primary, Pinon, P, primary, Tsoref, O, primary, Thaler, B, primary, Fraga-Silva, RA, primary, Fuijkschot, WW, primary, Shaaban, MNS, primary, Matthaeus, C, primary, Deluyker, D, primary, Scardigli, M, primary, Zahradnikova, A, primary, Dominguez, A, primary, Kondrat'eva, D, primary, Sosorburam, T, primary, Murarikova, M, primary, Duerr, GD, primary, Griecsova, L, primary, Portnichenko, VI, primary, Smolina, N, primary, Duicu, OANA M, primary, Elder, JM, primary, Zaglia, T, primary, Lorenzon, A, primary, Ruperez, C, primary, Woudstra, L, primary, Suffee, N, primary, De Lucia, C, primary, Russell-Hallinan, A, primary, Menendez-Montes, I, primary, Kapelko, VI, primary, Emmens, RW, primary, Hetman, O, primary, Van Der Laarse, WJ, primary, Goncharov, S, primary, Adao, R, primary, Huisamen, B, primary, Sirenko, O, primary, Nassiri, I, primary, Tserendavaa, SUMIYA, primary, Yushko, K, primary, Baldan Martin, M, primary, Falcone, C, primary, Vigorelli, V, additional, Nigro, P, additional, Pompilio, G, additional, Stepanova, O, additional, Valikhov, M, additional, Samko, A, additional, Masenko, V, additional, Tereschenko, S, additional, Teoh, T, additional, Domenjo-Vila, E, additional, Theologou, T, additional, Field, M, additional, Awad, W, additional, Yasin, M, additional, Nadal-Ginard, B, additional, Ellison-Hughes, GM, additional, Hellen, N, additional, Vittay, O, additional, Harding, SE, additional, Gomez-Cid, L, additional, Fernandez-Santos, ME, additional, Suarez-Sancho, S, additional, Plasencia, V, additional, Climent, A, additional, Sanz-Ruiz, R, additional, Hedhammar, M, additional, Atienza, F, additional, Fernandez-Aviles, F, additional, Kiamehr, M, additional, Oittinen, M, additional, Viiri, KM, additional, Kaikkonen, M, additional, Aalto-Setala, K, additional, Diolaiuti, L, additional, Laurino, A, additional, Sartiani, L, additional, Vona, A, additional, Zanardelli, M, additional, Cerbai, E, additional, Failli, P, additional, Hortigon-Vinagre, MP, additional, Van Der Heyden, M, additional, Burton, FL, additional, Smith, GL, additional, Watson, S, additional, Scigliano, M, additional, Tkach, S, additional, Alayoubi, S, additional, Terracciano, CM, additional, Ly, HQ, additional, Mauretti, A, additional, Van Marion, MH, additional, Van Turnhout, MC, additional, Van Der Schaft, DWJ, additional, Sahlgren, CM, additional, Goumans, MJ, additional, Bouten, CVC, additional, Vuorenpaa, H, additional, Penttinen, K, additional, Sarkanen, R, additional, Ylikomi, T, additional, Heinonen, T, additional, Grimaldi, V, additional, Aprile, M, additional, Esposito, R, additional, Maiello, C, additional, Soricelli, A, additional, Colantuoni, V, additional, Costa, V, additional, Ciccodicola, A, additional, Napoli, C, additional, Rowe, GC, additional, Johnson, K, additional, Arany, ZP, additional, Del Monte, F, additional, D'aurizio, R, additional, Kusmic, C, additional, Nicolini, G, additional, Baumgart, M, additional, Groth, M, additional, Ucciferri, N, additional, Iervasi, G, additional, Pitto, L, additional, Pipicz, M, additional, Gaspar, R, additional, Siska, A, additional, Foldesi, I, additional, Kiss, K, additional, Bencsik, P, additional, Thum, T, additional, Batkai, S, additional, Csont, T, additional, Haan, JJ, additional, Bosch, L, additional, Brans, MAD, additional, Van De Weg, SM, additional, Deddens, JC, additional, Lee, SJ, additional, Sluijter, JPG, additional, Pasterkamp, G, additional, Werner, I, additional, Projahn, D, additional, Staudt, M, additional, Curaj, A, additional, Soenmez, TT, additional, Simsekyilmaz, S, additional, Hackeng, TM, additional, Von Hundelshausen, P, additional, Koenen, RR, additional, Weber, C, additional, Liehn, EA, additional, Santos-Martinez, M, additional, Medina, C, additional, Watson, C, additional, Mcdonald, K, additional, Gilmer, J, additional, Ledwidge, M, additional, Song, SH, additional, Lee, MY, additional, Park, MH, additional, Choi, JC, additional, Ahn, JH, additional, Park, JS, additional, Oh, JH, additional, Choi, JH, additional, Lee, HC, additional, Cha, KS, additional, Hong, TJ, additional, Kudryavtsev, I, additional, Serebryakova, M, additional, Malashicheva, A, additional, Shishkova, A, additional, Zhiduleva, E, additional, Moiseeva, O, additional, Durisova, M, additional, Blaha, M, additional, Melenovsky, V, additional, Pirk, J, additional, Kautzner, J, additional, Petelina, TI, additional, Gapon, LI, additional, Gorbatenko, EA, additional, Potolinskaya, YV, additional, Arkhipova, EV, additional, Solodenkova, KS, additional, Osadchuk, MA, additional, Dutra, MF, additional, Oliveira, FCB, additional, Silva, MM, additional, Passos-Silva, DG, additional, Goncalves, R, additional, Santos, RAS, additional, Da Silva, RF, additional, Gavrilescu, CM, additional, Paraschiv, CM, additional, Manea, P, additional, Strat, LC, additional, Gomez, JMG, additional, Merino, D, additional, Hurle, MA, additional, Nistal, JF, additional, Aires, A, additional, Cortajarena, AL, additional, Villar, AV, additional, Abramowitz, J, additional, Birnbaumer, L, additional, Gourine, AV, additional, Tinker, A, additional, Takamura, M, additional, Takashima, S, additional, Inoue, O, additional, Misu, H, additional, Takamura, T, additional, Kaneko, S, additional, Alieva, TOHIRA, additional, Mougenot, N, additional, Dufilho, M, additional, Hatem, S, additional, Siegbahn, A, additional, Kostina, AS, additional, Uspensky, VE, additional, Moiseeva, OM, additional, Kostareva, AA, additional, Malashicheva, AB, additional, Van Dijk, CGM, additional, Chrifi, I, additional, Verhaar, MC, additional, Duncker, DJ, additional, Cheng, C, additional, Sturza, A, additional, Petrus, A, additional, Duicu, O, additional, Kiss, L, additional, Danila, M, additional, Baczko, I, additional, Jost, N, additional, Gotzhein, F, additional, Schon, J, additional, Schwarzl, M, additional, Hinrichs, S, additional, Blankenberg, S, additional, Volker, U, additional, Hammer, E, additional, Westermann, D, additional, Martinez-Martinez, E, additional, Arrieta, V, additional, Fernandez-Celis, A, additional, Jimenez-Alfaro, L, additional, Melero, A, additional, Alvarez-Asiain, V, additional, Cachofeiro, V, additional, Lopez-Andres, N, additional, Tribulova, N, additional, Wallukat, G, additional, Knezl, V, additional, Radosinska, J, additional, Barancik, M, additional, Tsinlikov, I, additional, Tsinlikova, I, additional, Nicoloff, G, additional, Blazhev, A, additional, Pesevski, Z, additional, Kvasilova, A, additional, Stopkova, T, additional, Eckhardt, A, additional, Buffinton, C M, additional, Nanka, O, additional, Kercheva, M, additional, Suslova, T, additional, Gusakova, A, additional, Ryabova, T, additional, Markov, V, additional, Karpov, R, additional, Seemann, H, additional, Alcantara, TC, additional, Santuchi, M DE C, additional, Fonseca, SG, additional, Barallobre-Barreiro, J, additional, Oklu, R, additional, Fava, M, additional, Baig, F, additional, Yin, X, additional, Albadawi, H, additional, Jahangiri, M, additional, Stoughton, J, additional, Mayr, M, additional, Podliesna, SP, additional, Veerman, CCV, additional, Verkerk, AOV, additional, Klerk, MK, additional, Lodder, EML, additional, Mengarelli, IM, additional, Bezzina, CRB, additional, Remme, CAR, additional, Takacs, H, additional, Polyak, A, additional, Morvay, N, additional, Lepran, I, additional, Tiszlavicz, L, additional, Nagy, N, additional, Ordog, B, additional, Farkas, A, additional, Forster, T, additional, Varro, A, additional, Farkas, AS, additional, Jayaprakash, P, additional, Parekh, K, additional, Ferdous, Z, additional, Oz, M, additional, Dobrzynski, H, additional, Adrian, TE, additional, Landi, S, additional, Bonzanni, M, additional, D'souza, A, additional, Boyett, M, additional, Bucchi, A, additional, Baruscotti, M, additional, Difrancesco, D, additional, Barbuti, A, additional, Kui, P, additional, Oravecz, K, additional, Hezso, T, additional, Levijoki, J, additional, Pollesello, P, additional, Koskelainen, T, additional, Otsomaa, L, additional, Farkas, A S, additional, Papp, JGY, additional, Toth, A, additional, Acsai, K, additional, Dini, L, additional, Mazzoni, L, additional, Mugelli, A, additional, Svatunkova, J, additional, Sedmera, D, additional, Deffge, C, additional, Baer, C, additional, Weinert, S, additional, Braun-Dullaeus, RC, additional, Herold, J, additional, Cassar, AC, additional, Zahra, GZ, additional, Pllaha, EP, additional, Dingli, PD, additional, Montefort, SM, additional, Xuereb, RGX, additional, Aschacher, T, additional, Messner, B, additional, Eichmair, E, additional, Mohl, W, additional, Reglin, B, additional, Rong, W, additional, Nitzsche, B, additional, Maibier, M, additional, Guimaraes, P, additional, Ruggeri, A, additional, Secomb, TW, additional, Pries, AR, additional, Baranowska-Kuczko, M, additional, Karpinska, O, additional, Kusaczuk, M, additional, Malinowska, B, additional, Kozlowska, H, additional, Demikhova, N, additional, Vynnychenko, L, additional, Prykhodko, O, additional, Grechanyk, N, additional, Kuryata, A, additional, Cottrill, KA, additional, Du, L, additional, Bjorck, HM, additional, Maleki, S, additional, Franco-Cereceda, A, additional, Chan, SY, additional, Eriksson, P, additional, Giebe, S, additional, Cockcroft, N, additional, Hewitt, K, additional, Brux, M, additional, Brunssen, C, additional, Tarasov, AA, additional, Davidov, SI, additional, Reznikova, EA, additional, Tapia Abellan, A, additional, Angosto Bazarra, D, additional, Pelegrin Vivancos, P, additional, Montoro Garcia, S, additional, Kastl, SP, additional, Pongratz, T, additional, Goliasch, G, additional, Gaspar, L, additional, Maurer, G, additional, Huber, K, additional, Dostal, E, additional, Pfaffenberger, S, additional, Oravec, S, additional, Wojta, J, additional, Speidl, WS, additional, Osipova, I, additional, Sopotova, I, additional, Eligini, S, additional, Cosentino, N, additional, Marenzi, G, additional, Tremoli, E, additional, Rami, M, additional, Ring, L, additional, Steffens, S, additional, Gur, O, additional, Gurkan, S, additional, Mangold, A, additional, Scherz, T, additional, Panzenboeck, A, additional, Staier, N, additional, Heidari, H, additional, Mueller, J, additional, Lang, IM, additional, Gatsiou, A, additional, Stamatelopoulos, K, additional, Perisic, L, additional, John, D, additional, Lunella, FF, additional, Hedin, U, additional, Zeiher, A, additional, Dimmeler, S, additional, Nunez, L, additional, Moure, R, additional, Marron-Linares, G, additional, Flores, X, additional, Aldama, G, additional, Salgado, J, additional, Calvino, R, additional, Tomas, M, additional, Bou, G, additional, Vazquez, N, additional, Hermida-Prieto, M, additional, Vazquez-Rodriguez, JM, additional, Amit, U, additional, Landa, N, additional, Kain, D, additional, Tyomkin, D, additional, David, A, additional, Leor, J, additional, Hohensinner, PJ, additional, Baumgartner, J, additional, Krychtiuk, KA, additional, Baik, N, additional, Miles, LA, additional, Seeman, H, additional, Montecucco, F, additional, Da Silva, AR, additional, Costa-Fraga, FP, additional, Anguenot, L, additional, Mach, FP, additional, Stergiopulos, N, additional, Kupreishvili, K, additional, Vonk, ABA, additional, Smulders, YM, additional, Van Hinsbergh, VWM, additional, Stooker, W, additional, Niessen, HWM, additional, Krijnen, PAJ, additional, Ashmawy, MM, additional, Salama, MA, additional, Elamrosy, MZ, additional, Juettner, R, additional, Rathjen, F G, additional, Bito, V, additional, Crocini, C, additional, Ferrantini, C, additional, Gabbrielli, T, additional, Silvestri, L, additional, Coppini, R, additional, Tesi, C, additional, Poggesi, C, additional, Pavone, FS, additional, Sacconi, L, additional, Mackova, K, additional, Zahradnik, I, additional, Zahradnikova, A, additional, Diaz, I, additional, Sanchez De Rojas De Pedro, E, additional, Hmadcha, K, additional, Calderon Sanchez, E, additional, Benitah, JP, additional, Gomez, AM, additional, Smani, T, additional, Ordonez, A, additional, Afanasiev, SA, additional, Egorova, MV, additional, Popov, SV, additional, Wu Qing, P, additional, Cheng, X, additional, Carnicka, S, additional, Pancza, D, additional, Jasova, M, additional, Kancirova, I, additional, Ferko, M, additional, Ravingerova, T, additional, Wu, S, additional, Schneider, M, additional, Marggraf, V, additional, Verfuerth, L, additional, Frede, S, additional, Boehm, O, additional, Dewald, O, additional, Baumgarten, G, additional, Kim, S-C, additional, Farkasova, V, additional, Gablovsky, I, additional, Bernatova, I, additional, Nosar, V, additional, Portnychenko, A, additional, Drevytska, T, additional, Mankovska, I, additional, Gogvadze, V, additional, Sejersen, T, additional, Kostareva, A, additional, Wolf, A, additional, Privistirescu, A, additional, Muntean, D, additional, O ' Gara, P, additional, Sanchez-Alonso, JL, additional, Lyon, AR, additional, Prando, V, additional, Pianca, N, additional, Lo Verso, F, additional, Milan, G, additional, Pesce, P, additional, Sandri, M, additional, Mongillo, M, additional, Beffagna, G, additional, Poloni, G, additional, Dazzo, E, additional, Sabatelli, P, additional, Doliana, R, additional, Polishchuk, R, additional, Carnevale, D, additional, Lembo, G, additional, Bonaldo, P, additional, Braghetta, P, additional, Rampazzo, A, additional, Cairo, M, additional, Giralt, M, additional, Villarroya, F, additional, Planavila, A, additional, Biesbroek, PS, additional, Emmens, RWE, additional, Juffermans, LJM, additional, Van Der Wall, AC, additional, Van Rossum, AC, additional, Niessen, JWM, additional, Moor Morris, T, additional, Dilanian, G, additional, Farahmand, P, additional, Puceat, M, additional, Gambino, G, additional, Petraglia, L, additional, Elia, A, additional, Komici, K, additional, Femminella, GD, additional, D'amico, ML, additional, Pagano, G, additional, Cannavo, A, additional, Liccardo, D, additional, Koch, WJ, additional, Nolano, M, additional, Leosco, D, additional, Ferrara, N, additional, Rengo, G, additional, Neary, R, additional, Shiels, L, additional, Baugh, J, additional, Palacios, B, additional, Escobar, B, additional, Alonso, AV, additional, Guzman, G, additional, Ruiz-Cabello, J, additional, Jimenez-Borreguero, LJ, additional, Martin-Puig, S, additional, Lakomkin, VL, additional, Lukoshkova, EV, additional, Abramov, AA, additional, Gramovich, VV, additional, Vyborov, ON, additional, Ermishkin, VV, additional, Undrovinas, NA, additional, Shirinsky, VP, additional, Smilde, BJ, additional, Woudstra, L, additional, Fong Hing, G, additional, Wouters, D, additional, Zeerleder, S, additional, Murk, JL, additional, Van Ham, SM, additional, Heymans, S, additional, Krakhmalova, O, additional, Van Groen, D, additional, Bogaards, SJP, additional, Schalij, I, additional, Portnichenko, GV, additional, Tumanovska, LV, additional, Goshovska, YV, additional, Lapikova-Bryhinska, TU, additional, Nagibin, VS, additional, Dosenko, VE, additional, Mendes-Ferreira, P, additional, Maia-Rocha, C, additional, Santos-Ribeiro, D, additional, Potus, F, additional, Breuils-Bonnet, S, additional, Provencher, S, additional, Bonnet, S, additional, Rademaker, M, additional, Leite-Moreira, AF, additional, Bras-Silva, C, additional, Lopes, J, additional, Kuryata, O, additional, Lusynets, T, additional, Alikulov, I, additional, Nourddine, M, additional, Azzouzi, L, additional, Habbal, R, additional, Tserendavaa, SUMIYA, additional, Enkhtaivan, ODKHUU, additional, Shagdar, ZORIGO, additional, Malchinkhuu, MUNKHZ, additional, Malchinkhuu, MUNLHZ, additional, Koval, S, additional, Starchenko, T, additional, Mourino-Alvarez, L, additional, Gonzalez-Calero, L, additional, Sastre-Oliva, T, additional, Lopez, JA, additional, Vazquez, J, additional, Alvarez-Llamas, G, additional, Ruilope, LUIS M, additional, De La Cuesta, F, additional, Barderas, MG, additional, Bozzini, S, additional, D'angelo, A, additional, and Pelissero, G, additional

Published
2016
Full Text
View/download PDF

3. Poster session 2Morphogenetic mechanisms290MiR-133 regulates retinoic acid pathway during early cardiac chamber specification291Bmp2 regulates atrial differentiation through miR-130 during early heart looping formationDevelopmental genetics294Association of deletion allele of insertion/deletion polymorphism in alpha 2B adrenoceptor gene and hypertension with or without type 2 diabetes mellitus295Association of G1359A polymorphism of the endocannabinoid type 1 receptor (CNR1) with coronary artery disease (CAD) with type 2 diabetes mellitusCell growth, differentiation and stem cells - Vascular298Gamma-secretase inhibitor prevents proliferation and migration of ductus arteriosus smooth muscle cells: a role of Notch signaling in postnatal closure of ductus arteriosus299Mesenchymal stromal-like cells (MLCs) derived from induced pluripotent stem (iPS) cells: a promising therapeutic option to promote neovascularization300Sonic Hedgehog promotes mesenchymal stem cell differentiation to vascular smooth muscle cells in cardiovacsular disease301Proinflammatory cytokine secretion and epigenetic modification in endothelial cells treated LPS-GinfivalisCell death and apoptosis - Vascular304Mitophagy acts as a safeguard mechanism against human vascular smooth muscle cell apoptosis induced by atherogenic lipidsTranscriptional control and RNA species - Vascular307MicroRNA-34a role in vascular calcification308Local delivery of a miR-146a inhibitor utilizing a clinically applicable approach attenuates neointima formation after vascular injury309Long noncoding RNA landscape of hypoxic endothelial cells310Specific circulating microRNAs levels associate with hypertension, hyperglycemia and dysfunctional HDL in acute coronary syndrome patientsCytokines and cellular inflammation - Vascular313Phosphodiesterase5A up-regulation in vascular endothelium under pro-inflammatory conditions: a newly disclosed anti-inflammatory activity for the omega-3polyunsaturated aatty acid docosahexaenoic acid314Cardiovascular risk modifying with extra-low dose anticytokine drugs in rhematoid arthritis315Conversion of human M-CSF macrophages into foam cells reduces their proinflammatory responses to classical M1-polarizing activation316Lymphocytic myocarditis coincides with increased plaque inflammation and plaque hemorrhage in coronary arteries, facilitating myocardial infarction317Serum osteoprotegerin level predictsdeclined numerous of circulating endothelial- derived and mononuclear-derived progenitor cells in patients with metabolic syndromeGrowth factors and neurohormones - Vascular320Effect of gastrin-releasing peptide (GRP) on vascular inflammationSignal transduction - Heart323A new synthetic peptide regulates hypertrophy in vitro through means of the inhibition of nfkb324Inducible fibroblast-specific knockout of p38 alpha map kinase is cardioprotective in a mouse model of isoproterenol-induced cardiac hypertrophy325Regulation of beta-adrenoceptor-evoked inotropic responses by inhibitory G protein, adenylyl cyclase isoforms 5 and 6 and phosphodiesterases326Binding to RGS3 and stimulation of M2 muscarinic acetylcholine receptors modulates the substrate specificity of p190RhoGAP in cardiac myocytes327Cardiac regulation of post-translational modifications, parylation and deacetylation in LMNA dilated cardiomyopathy mouse model328Beta-adrenergic regulation of the b56delta/pp2a holoenzyme in cardiac myocytes through b56delta phosphorylation at serine 573Nitric oxide and reactive oxygen species - Vascular331Oxidative stress-induced miR-200c disrupts the regulatory loop among SIRT1, FOXO1 and eNOS332Antioxidant therapy prevents oxidative stress-induced endothelial dysfunction and Enhances Wound Healing333Morphological and biochemical characterization of red blood cell in coronary artery diseaseCytoskeleton and mechanotransduction - Heart336Novel myosin activator, JSH compounds, increased myocardial contractility without chronotropic effect in ratsExtracellular matrix and fibrosis - Vascular339Ablation of Toll-like receptor 9 causes cardiac rupture after myocardial infarction by attenuating proliferation and differentiation of cardiac fibroblasts340Altered vascular remodeling in the mouse hind limb ischemia model in Factor VII activating protease (FSAP) deficiencyVasculogenesis, angiogenesis and arteriogenesis343Pro-angiogenic effects of proly-hydroxylase inhibitors and their potential for use in a novel strategy of therapeutic angiogenesis for coronary total occlusion344Nrf2 drives angiogenesis in transcription-independent manner: new function of the master regulator of oxidative stress response345Angiogenic gene therapy, despite efficient vascular growth, is not able to improve muscle function in normoxic or chronically ischemic rabbit hindlimbs -role of capillary arterialization and shunting346Effect of PAR-1 inhibition on collateral vessel growth in the murine hind limb model347Quaking is a key regulator of endothelial cell differentiation, neovascularization and angiogenesis348"Emerging angiogenesis" in the chick chorioallantoic membrane (CAM). An in vivo study349Exosomes from cardiomyocyte progenitor cells and mesenchymal stem cells stimulate angiogenesis in vitro and in vivo via EMMPRINEndothelium352Reciprocal regulation of GRK2 and bradykinin receptor stimulation modulate Ca2+ intracellular level in endothelial cells353The roles of bone morphogenetic proteins 9 and 10 in endothelial inflammation and atherosclerosis354The contribution of GPR55 to the L-alpha-lysophosphatidylinositol-induced vasorelaxation in isolated human pulmonary arteries355The endothelial protective ACE inhibitor Zofenoprilat exerts anti-inflammatory activities through H2S production356A new class of glycomimetic drugs to prevent free fatty acid-induced endothelial dysfunction357Endothelial progenitor cells to apoptotic endothelial cell-derived microparticles ration differentiatesas preserved from reduced ejection fractionheart failure358Proosteogenic genes are activated in endothelial cells of patients with thoracic aortic aneurysm359Endothelin ETB receptors mediate relaxing responses to insulin in pericardial resistance arteries from patients with cardiovascular disease (CVD)Smooth muscle and pericytes362CX3CR1 positive myeloid cells regulate vascular smooth muscle tone by inducing calcium oscillations via activation of IP3 receptors363A novel function of PI3Kg on cAMP regulation, role in arterial wall hyperplasia through modulation of smooth muscle cells proliferation364NRP1 and NRP2 play important roles in the development of neointimal hyperplasia in vivo365Azithromycin induces autophagy in aortic smooth muscle cellsCoagulation, thrombosis and platelets368The real time in vivo evaluation of platelet-dependent aldosterone prothrombotic action in mice369Development of a method for in vivo detection of active thrombi in mice370The antiplatelet effects of structural analogs of the taurine chloramine371The influence of heparin anticoagulant drugs on functional state of human platelets372Regulation of platelet aggregation and adenosine diphosphate release by d dimer in acute coronary syndrome (in vitro study)Oxygen sensing, ischaemia and reperfusion375Sirtuin 5 mediates brain injury in a mouse model of cerebral ischemia-reperfusion376Abscisic acid: a new player in cardiomyocyte protection from ischaemia?377Protective effects of ultramicronized palmitoylethanolamide (PEA-um) in myocardial ischaemia and reperfusion injury in vivo378Identification of stem cell-derived cardiomyocytes using cardiac specific markers and additional testing of these cells in simulated ischemia/reperfusion system379Single-dose intravenous metformin treatment could afford significant protection of the injured rat kidney in an experimental model of ischemia-reperfusion380Cardiotoxicity of long acting muscarinic receptor antagonists used for chronic obstructive pulmonary disease381Dependence antioxidant potential on the concentration of amino acids382The impact of ischemia-reperfusion on physiological parameters,apoptosis and ultrastructure of rabbit myocardium with experimental aterosclerosisMitochondria and energetics385MicroRNA-1 dependent regulation of mitochondrial calcium uniporter (MCU) in normal and hypertrophied hearts386Mitochondrial homeostasis and cardioprotection: common targets for desmin and aB-crystallin387Overexpression of mitofusin-2 (Mfn2) and associated mitochondrial dysfunction in the diabetic heart388NO-dependent prevention of permeability transition pore (MPTP) opening by H2S and its regulation of Ca2+ accumulation in rat heart mitochondria389G protein coupled receptor kinase 2 (GRK2) is fundamental in recovering mitochondrial morphology and function after exposure to ionizing radiation (IR)Gender issues392Sex differences in pulmonary vascular control; focus on the nitric oxide pathwayAging395Heart failure with preserved ejection fraction develops when feeding western diet to senescence-accelerated mice396Cardiovascular markers as predictors of cognitive decline in elderly hypertensive patients397Changes in connexin43 in old rats with volume overload chronic heart failureGenetics and epigenetics400Calcium content in the aortic valve is associated with 1G>2G matrix metalloproteinase 1 polymorphism401Neuropeptide receptor gene s (NPSR1) polymorphism and sleep disturbances402Endothelin-1 gene Lys198Asn polymorphism in men with essential hypertension complicated and uncomplicated with chronic heart failure403Association of common polymorphisms of the lipoprotein lipase and pon1 genes with the metabolic syndrome in a sample of community participantsGenomics, proteomics, metabolomics, lipidomics and glycomics405Gene expression quantification using multiplexed color-coded probe pairs to determine RNA content in sporadic cardiac myxoma406Large-scale phosphorylation study of the type 2 diabetic heart subjected to ischemia / reperfusion injury407Transcriptome-based identification of new anti-inflammatory properties of the olive oil hydroxytyrosol in vascular endothelial cell under basal and proinflammatory conditions408Gene polymorphisms combinations and risk of myocardial infarctionComputer modelling, bioinformatics and big data411Comparison of the repolarization reserve in three state-of-the-art models of the human ventricular action potentialMetabolism, diabetes mellitus and obesity414Endothelial monocyte-activating polypeptide-II improves heart function in type -I Diabetes mellitus415Admission glucose level is independent predictor of impaired left ventricular function in patients with acute myocardial infarction: a two dimensional speckle-tracking echocardiography study416Association between biochemical markers of lipid profile and inflammatory reaction and stiffness of the vascular wall in hypertensive patients with abdominal obesity417Multiple common co-morbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress and myocardial stiffening418Investigating the cardiovascular effects of antiretroviral drugs in a lean and high fat/sucrose diet rat model of obesity419Statins in the treatment of non-alcoholic steatohepatitis (NASH). Our experience from a 2-year prospective study in Constanta County, Romania420Epicardial adipose tissue as a predictor of cardiovascular outcome in patients with ACS undergoing PCI?Arterial and pulmonary hypertension423Dependence between heart rhythm disorers and ID polymorphism of ACE gene in hypertensive patients424Molecular mechanisms underlying the beneficial effects of Urocortin 2 in pulmonary arterial hypertension425Inhibition of TGf-b axis and action of renin-angiotensin system in human ascending aorta aneurysms426Early signs of microcirculation and macrocirculation abnormalities in prehypertension427Vascular smooth muscle cell-expressed Tie-2 controls vascular tone428Cardiac and vascular remodelling in the development of chronic thrombo-embolic pulmonary hypertension in a novel swine modelBiomarkers431Arrhythmogenic cardiomyopathy: a new, non invasive biomarker432Can circulating microRNAs distinguish type 1 and type 2 myocardial infarction?433Design of a high-throughput multiplex proteomics assay to identify left ventricular diastolic dysfunction in diabetes434Monocyte-derived and P-selectin-carrying microparticles are differently modified by a low fat diet in patients with cardiovascular risk factors who will and who will not develop a cardiovascular event435Red blood cell distribution width assessment by polychromatic interference microscopy of thin films in chronic heart failure436Invasive and noninvasive evaluation of quality of radiofrequency-induced cardiac denervation in patients with atrial fibrillation437The effect of therapeutic hypothermia on the level of brain derived neurotrophic factor (BDNF) in sera following cardiopulmonary resustitation438Novel biomarkers to predict outcome in patients with heart failure and severe aortic stenosis439Biological factors linking depression and anxiety to cardiovascular disease440Troponins and myoglobin dynamic at coronary arteries graftingInvasive, non-invasive and molecular imaging443Diet composition effects on the genetic typing of the mouse ob mutation: a micro-ultrasound characterization of cardiac function, macro and micro circulation and liver steatosis444Characterization of pig coronary and rabbit aortic lesions using IV-OCT quantitative analysis: correlations with histologyGene therapy and cell therapy447Enhancing the survival and angiogenic potential of mouse atrial mesenchymal cells448VCAM-1 expression in experimental myocardial infarction and its relation to bone marrow-derived mononuclear cell retentionTissue engineering451Advanced multi layered scaffold that increases the maturity of stem cell-derived human cardiomyocytes452Response of engineered heart tissue to simulated ischemia/reperfusion in the presence of acute hyperglycemic conditions453Serum albumin hydrogels prevent de-differentiation of neonatal cardiomyocytes454A novel paintbrush technique for transfer of low viscosity ultraviolet light curable cyan methacrylate on saline immersed in-vitro sheep heart

Author

Garcia-Martinez, V, primary, Lopez Sanchez, C, primary, Hamed, W, primary, Hsu, JH, primary, Ferrer-Lorente, R, primary, Alshamrani, Maryam, primary, Pizzicannella, J, primary, Vindis, C, primary, Badi, I, primary, Korte, L, primary, Voellenkle, C, primary, Niculescu, L S, primary, Massaro, M, primary, Babaeva, AR, primary, Da Silva, F, primary, Woudstra, L, primary, Berezin, A, primary, Bae, MK, primary, Del Giudice, C, primary, Bageghni, S A, primary, Krobert, K, primary, Levay, M, primary, Vignier, N, primary, Ranieri, A, primary, Magenta, A, primary, Orlandi, A, primary, Porro, B, primary, Jeon, E-S, primary, Omori, Y, primary, Herold, J, primary, Barnett, G A, primary, Grochot-Przeczek, A, primary, Korpisalo, P, primary, Deffge, C, primary, Margariti, A, primary, Rong, W, primary, Maring, JA, primary, Gambardella, J, primary, Mitrofan, CG, primary, Karpinska, O, primary, Morbidelli, L, primary, Wilkinson, FL, primary, Kostina, AS, primary, De Mey, J G R, primary, Kumar, A, primary, Lupieri, A, primary, Pellet-Many, C, primary, Stamatiou, R, primary, Gromotowicz, A, primary, Dickhout, A, primary, Murina, M, primary, Roka-Moiia, YM, primary, Malinova, L, primary, Diaz-Canestro, C, primary, Vigliarolo, T, primary, Cuzzocrea, S, primary, Szantai, A, primary, Medic, B, primary, Cassambai, S, primary, Korda, A, primary, Revnic, C R, primary, Borile, G, primary, Diokmetzidou, A, primary, Murfitt, L, primary, Budko, A, primary, Fiordelisi, A, primary, De Wijs-Meijler, DPM, primary, Gevaert, AB, primary, Noriega De La Colina, A, primary, Benes, J, primary, Guillermo Solache Berrocal, GSB, primary, Gafarov, V, primary, Zhebel, VM, primary, Prakaschandra, R, primary, Stepien, E L, primary, Smith, LE, primary, Carluccio, MA, primary, Timasheva, Y, primary, Paci, M, primary, Dorofeyeva, N A, primary, Chimed, CH, primary, Petelina, TI, primary, Sorop, O, primary, Genis, A, primary, Parepa, I R, primary, Tscharre, M, primary, Krestjyaninov, MV, primary, Maia-Rocha, C, primary, Borges, L, primary, Sasonko, M L, primary, Kapel, SS, primary, Stam, K, primary, Sommariva, E, primary, Stojkovic, S, primary, O'reilly, J, primary, Chiva-Blanch, G, primary, Evtushenko, A, primary, Skopal, J, primary, Sunderland, N, primary, Gegenava, T, primary, Charnaia, MA, primary, Di Lascio, N, primary, Tarvainen, SJ, primary, Malandraki-Miller, S, primary, Uitterdijk, A, primary, Benzoni, P, primary, Ruivo, E, primary, Humphrey, E J, primary, Arokiaraj, MC, primary, Franco, D, additional, Garcia-Lopez, V, additional, Aranega, A, additional, Lopez-Sanchez, C, additional, Garcia-Martinez, V, additional, Tayel, S, additional, Khader, H, additional, El-Helbawy, N, additional, Alrefai, A, additional, El-Barbary, H, additional, Wu, JR, additional, Dai, ZK, additional, Yeh, JL, additional, Sanjurjo-Rodriguez, C, additional, Richaud-Patin, Y, additional, Blanco, FJ, additional, Badimon, L, additional, Raya, A, additional, Cahill, Paul A, additional, Diomede, F, additional, Merciaro, I, additional, Trubiani, O, additional, Nahapetyan, H, additional, Swiader, A, additional, Faccini, J, additional, Boya, P, additional, Elbaz, M, additional, Zeni, F, additional, Burba, I, additional, Bertolotti, M, additional, Capogrossi, MC, additional, Pompilio, G, additional, Raucci, A, additional, Widmer-Teske, R, additional, Dutzmann, J, additional, Bauersachs, J, additional, Donde, K, additional, Daniel, JM, additional, Sedding, DG, additional, Simionescu, N, additional, Sanda, GM, additional, Carnuta, MG, additional, Stancu, CS, additional, Popescu, AC, additional, Popescu, MR, additional, Vlad, A, additional, Dimulescu, DR, additional, Sima, AV, additional, Scoditti, E, additional, Pellegrino, M, additional, Calabriso, N, additional, Carluccio, MA, additional, Storelli, C, additional, De Caterina, R, additional, Solodenkova, KS, additional, Kalinina, EV, additional, Usachiova, MN, additional, Lappalainen, J, additional, Lee-Rueckert, M DE C, additional, Kovanen, PT, additional, Biesbroek, PS, additional, Emmens, RWE, additional, Van Rossum, AC, additional, Juffermans, LJM, additional, Niessen, JWM, additional, Krijnen, PAJ, additional, Kremzer, A, additional, Samura, T, additional, Berezina, T, additional, Gronenko, E, additional, Kim, MK, additional, Park, HJ, additional, Bae, SK, additional, Sorriento, D, additional, Ciccarelli, M, additional, Vernieri, E, additional, Campiglia, P, additional, Trimarco, B, additional, Iaccarino, G, additional, Hemmings, K E, additional, Porter, K E, additional, Ainscough, J F, additional, Drinkhill, M J, additional, Turner, N A, additional, Hiis, HG, additional, Cosson, MV, additional, Levy, FO, additional, Wieland, T, additional, Macquart, C, additional, Chatzifrangkeskou, M, additional, Evans, A, additional, Bonne, G, additional, Muchir, A, additional, Kemp, E, additional, Avkiran, M, additional, Carlomosti, F, additional, D'agostino, M, additional, Beji, S, additional, Zaccagnini, G, additional, Maimone, B, additional, Di Stefano, V, additional, De Santa, F, additional, Cordisco, S, additional, Antonini, A, additional, Ciarapica, R, additional, Dellambra, E, additional, Martelli, F, additional, Avitabile, D, additional, Scioli, MG, additional, Bielli, A, additional, Agostinelli, S, additional, Tarquini, C, additional, Tarallo, V, additional, De Falco, S, additional, Zaninoni, A, additional, Fiorelli, S, additional, Bianchi, P, additional, Teruzzi, G, additional, Squellerio, I, additional, Turnu, L, additional, Lualdi, A, additional, Tremoli, E, additional, Cavalca, V, additional, Lee, YJ, additional, Ju, ES, additional, Choi, JO, additional, Lee, GY, additional, Lim, BK, additional, Manickam, MANOJ, additional, Jung, S-H, additional, Omiya, S, additional, Otsu, K, additional, Deffge, C, additional, Nowak, S, additional, Wagner, M, additional, Braun-Dullaeus, RC, additional, Kostin, S, additional, Francke, A, additional, Subramaniam, S, additional, Kanse, SM, additional, Al-Lamee, K, additional, Schofield, CJ, additional, Egginton, S, additional, Gershlick, AH, additional, Kloska, D, additional, Kopacz, A, additional, Augustyniak, A, additional, Dulak, J, additional, Jozkowicz, A, additional, Hytonen, J, additional, Halonen, P, additional, Taavitsainen, J, additional, Tarvainen, S, additional, Hiltunen, T, additional, Liimatainen, T, additional, Kalliokoski, K, additional, Knuuti, J, additional, Yla-Herttuala, S, additional, Weinert, S, additional, Isermann, B, additional, Lee, J, additional, Herold, J, additional, Cochrane, A, additional, Kelaini, S, additional, Bojdo, J, additional, Vila Gonzalez, M, additional, Hu, Y, additional, Grieve, D, additional, Stitt, A W, additional, Zeng, L, additional, Xu, Q, additional, Margariti, A, additional, Reglin, B, additional, Xiang, W, additional, Nitzsche, B, additional, Maibier, M, additional, Pries, AR, additional, Vrijsen, KR, additional, Chamuleau, SAJ, additional, Verhage, V, additional, Metz, CHG, additional, Lodder, K, additional, Van Eeuwijk, ECM, additional, Van Dommelen, SM, additional, Doevendans, PA, additional, Smits, AM, additional, Goumans, MJ, additional, Sluijter, JPG, additional, Bova, M, additional, Loffredo, S, additional, Appleby, S, additional, Morrell, N, additional, Baranowska-Kuczko, M, additional, Kloza, M, additional, Ambrozewicz, E, additional, Kozlowski, M, additional, Malinowska, B, additional, Kozlowska, H, additional, Monti, M, additional, Terzuoli, E, additional, Ziche, M, additional, Mahmoud, AM, additional, Jones, AM, additional, Wilkinson, JA, additional, Romero, M, additional, Duarte, J, additional, Alexander, MY, additional, Faggian, G, additional, Kostareva, AA, additional, Malashicheva, AB, additional, Leurgans, TM, additional, Nguyen, TN, additional, Irmukhamedov, A, additional, Riber, LP, additional, Mcgeogh, R, additional, Comer, S, additional, Blanco Fernandez, A, additional, Ghigo, A, additional, Blaise, R, additional, Smirnova, NF, additional, Malet, N, additional, Vincent, P, additional, Limon, I, additional, Gayral, S, additional, Hirsch, E, additional, Laffargue, M, additional, Mehta, V, additional, Zachary, I, additional, Aidonidis, I, additional, Kramkowski, K, additional, Miltyk, W, additional, Kolodziejczyk, P, additional, Gradzka, A, additional, Szemraj, J, additional, Chabielska, E, additional, Dijkgraaf, I, additional, Bitsch, N, additional, Van Hoof, S, additional, Verhaegen, F, additional, Koenen, R, additional, Hackeng, TM, additional, Roshchupkin, D I, additional, Buravleva, K V, additional, Sergienko, VI, additional, Zhernossekov, DD, additional, Rybachuk, VM, additional, Grinenko, TV, additional, Furman, N, additional, Dolotovskaya, P, additional, Shamyunov, M, additional, Denisova, T, additional, Reiner, M, additional, Akhmedov, A, additional, Keller, S, additional, Miranda, M, additional, Briand, S, additional, Barile, L, additional, Kullak-Ublick, G, additional, Luscher, T, additional, Camici, G, additional, Guida, L, additional, Magnone, M, additional, Ameri, P, additional, Lazzarini, E, additional, Fresia, C, additional, Bruzzone, S, additional, Zocchi, E, additional, Di Paola, R, additional, Cordaro, M, additional, Crupi, R, additional, Siracusa, R, additional, Campolo, M, additional, Bruschetta, G, additional, Fusco, R, additional, Pugliatti, P, additional, Esposito, E, additional, Paloczi, J, additional, Ruivo, E, additional, Gaspar, R, additional, Dinnyes, A, additional, Kobolak, J, additional, Ferdinandy, P, additional, Gorbe, A, additional, Todorovic, Z, additional, Krstic, D, additional, Savic Vujovic, K, additional, Jovicic, D, additional, Basta Jovanovic, G, additional, Radojevic Skodric, S, additional, Prostran, M, additional, Dean, S, additional, Mee, CJ, additional, Harvey, KL, additional, Hussain, A, additional, Pena, C, additional, Paltineanu, B, additional, Voinea, S, additional, Revnic, F, additional, Ginghina, C, additional, Zaglia, T, additional, Ceriotti, P, additional, Campo, A, additional, Carullo, P, additional, Armani, A, additional, Coppini, R, additional, Vida, V, additional, Olivotto, I, additional, Stellin, G, additional, Rizzuto, R, additional, De Stefani, D, additional, Sandri, M, additional, Catalucci, D, additional, Mongillo, M, additional, Soumaka, E, additional, Kloukina, I, additional, Tsikitis, M, additional, Makridakis, M, additional, Varela, A, additional, Davos, C, additional, Vlachou, A, additional, Capetanaki, Y, additional, Iqbal, MM, additional, Bennett, H, additional, Davenport, B, additional, Pinali, C, additional, Cooper, G, additional, Cartwright, E, additional, Kitmitto, A, additional, Strutynska, NA, additional, Mys, LA, additional, Sagach, VF, additional, Franco, A, additional, Verzijl, A, additional, Stam, K, additional, Van Duin, R, additional, Reiss, IKM, additional, Duncker, DJ, additional, Merkus, D, additional, Shakeri, H, additional, Orije, M, additional, Leloup, AJ, additional, Van Hove, CE, additional, Van Craenenbroeck, EM, additional, De Meyer, GRY, additional, Vrints, CJ, additional, Lemmens, K, additional, Desjardins-Creapeau, L, additional, Wu, R, additional, Lamarre-Cliche, M, additional, Larochelle, P, additional, Bherer, L, additional, Girouard, H, additional, Melenovsky, M, additional, Kvasilova, A, additional, Benes, J, additional, Ruskova, K, additional, Sedmera, D, additional, Ana Barral, ABV, additional, Martin Fernandez, M, additional, Pablo Roman Garcia, PRG, additional, Juan Carlos Llosa, JCLL, additional, Manuel Naves Diaz, MND, additional, Cesar Moris, CM, additional, Jorge B Cannata-Andia, JBCA, additional, Isabel Rodriguez, IR, additional, Voevoda, M, additional, Gromova, E, additional, Maximov, V, additional, Panov, D, additional, Gagulin, I, additional, Gafarova, A, additional, Palahniuk, H, additional, Pashkova, IP, additional, Zhebel, NV, additional, Starzhynska, OL, additional, Naidoo, DP, additional, Rawojc, K, additional, Enguita, F J, additional, Grudzien, G, additional, Cordwell, SJ, additional, White, MY, additional, Massaro, M, additional, Martinelli, R, additional, Gatta, V, additional, Nasibullin, TR, additional, Erdman, VV, additional, Tuktarova, IA, additional, Mustafina, OE, additional, Hyttinen, J, additional, Severi, S, additional, Vorobyov, GG, additional, Batmyagmar, KH, additional, Lkhagvasuren, Z, additional, Gapon, LI, additional, Musikhina, NA, additional, Avdeeva, KS, additional, Dyachkov, SM, additional, Heinonen, I, additional, Van Kranenburg, M, additional, De Beer, VJ, additional, Octavia, Y, additional, Van Geuns, RJ, additional, Van Den Meiracker, AH, additional, Van Der Velden, J, additional, Everson, FP, additional, Ogundipe, T, additional, Grandjean, T, additional, De Boever, P, additional, Goswami, N, additional, Strijdom, H, additional, Suceveanu, A I, additional, Suceveanu, A P, additional, Mazilu, L, additional, Tofoleanu, D E, additional, Catrinoiu, D, additional, Rohla, M, additional, Hauser, C, additional, Huber, K, additional, Wojta, H, additional, Weiss, TW, additional, Melnikova, MA, additional, Olezov, NV, additional, Gimaev, RH, additional, Khalaf, H, additional, Ruzov, VI, additional, Adao, R, additional, Mendes-Ferreira, P, additional, Santos-Ribeiro, D, additional, Rademaker, M, additional, Leite-Moreira, AF, additional, Bras-Silva, C, additional, Alvarenga, LAA, additional, Falcao, RSP, additional, Dias, RR, additional, Lacchini, S, additional, Gutierrez, PS, additional, Michel, JB, additional, Gurfinkel, YU I, additional, Atkov, O YU, additional, Teichert, M, additional, Korn, C, additional, Mogler, C, additional, Hertel, S, additional, Arnold, C, additional, Korff, T, additional, Augustin, HG, additional, Van Duin, RWB, additional, De Wijs-Meijler, DPM, additional, D'alessandra, Y, additional, Farina, F M, additional, Casella, M, additional, Catto, V, additional, Carbucicchio, C, additional, Dello Russso, A, additional, Stadiotti, I, additional, Brambilla, S, additional, Chiesa, M, additional, Giacca, M, additional, Colombo, G I, additional, Tondo, C, additional, Ahlin, F, additional, Andric, T, additional, Tihanyi, D, additional, Wojta, J, additional, O'connell, E, additional, Butt, A, additional, Murphy, L, additional, Pennington, S, additional, Ledwidge, M, additional, Mcdonald, K, additional, Baugh, J, additional, Watson, C, additional, Suades, R, additional, Crespo, J, additional, Estruch, R, additional, Dyachenko, A, additional, Ryabukho, V, additional, Evtushenko, V, additional, Saushkina, YU, additional, Lishmanov, YU, additional, Smyshlyaev, K, additional, Bykov, A, additional, Popov, S, additional, Pavlyukova, E, additional, Anfinogenova, Y, additional, Szigetfu, E, additional, Kapornai, B, additional, Forizs, E, additional, Jenei, ZS, additional, Nagy, Z, additional, Merkely, B, additional, Zima, E, additional, Cai, A, additional, Dworakowski, R, additional, Gibbs, T, additional, Piper, S, additional, Jegard, N, additional, Mcdonagh, T, additional, Gegenava, M, additional, Dementieva, II, additional, Morozov, YUA, additional, Barsanti, C, additional, Stea, F, additional, Lenzarini, F, additional, Kusmic, C, additional, Faita, F, additional, Halonen, PJ, additional, Puhakka, PH, additional, Hytonen, JP, additional, Taavitsainen, JM, additional, Supit, E A, additional, Carr, C A, additional, Groenendijk, BCW, additional, Gorsse-Bakker, C, additional, Panasewicz, A, additional, Sneep, S, additional, Tempel, D, additional, Van Der Giessen, WJ, additional, Rys, J, additional, Daraio, C, additional, Dell'era, P, additional, Pigler, J, additional, Eder, A, additional, Eschenhagen, T, additional, Mazo, M M, additional, Amdursky, N, additional, Peters, N S, additional, Stevens, M M, additional, and Terracciano, C M, additional

Published
2016
Full Text
View/download PDF

4. Vasoprotective Endothelial Effects of Chronic Cannabidiol Treatment and Its Influence on the Endocannabinoid System in Rats with Primary and Secondary Hypertension.

Author

Baranowska-Kuczko M, Kozłowska H, Kloza M, Kusaczuk M, Harasim-Symbor E, Biernacki M, Kasacka I, and Malinowska B

Abstract

Our study aimed to examine the endothelium (vascular)-protecting effects of chronic cannabidiol (CBD) administration (10 mg/kg once daily for 2 weeks) in aortas and small mesenteric (G3) arteries isolated from deoxycorticosterone-induced hypertensive (DOCA-salt) rats and spontaneously hypertensive rats (SHR). CBD reduced hypertrophy and improved the endothelium-dependent vasodilation in response to acetylcholine in the aortas and G3 of DOCA-salt rats and SHR. The enhancement of vasorelaxation was prevented by the inhibition of nitric oxide (NO) with L-NAME and/or the inhibition of cyclooxygenase (COX) with indomethacin in the aortas and G3 of DOCA-salt and SHR, respectively. The mechanism of the CBD-mediated improvement of endothelial function in hypertensive vessels depends on the vessel diameter and may be associated with its NO-, the intermediate-conductance calcium-activated potassium channel- or NO-, COX-, the intermediate and the small-conductance calcium-activated potassium channels-dependent effect in aortas and G3, respectively. CBD increased the vascular expression of the cannabinoid CB 1 and CB 2 receptors and aortic levels of endocannabinoids with vasorelaxant properties e.g., anandamide, 2-arachidonoylglycerol and palmitoyl ethanolamide in aortas of DOCA-salt and/or SHR. In conclusion, CBD treatment has vasoprotective effects in hypertensive rats, in a vessel-size- and hypertension-model-independent manner, at least partly via inducing local vascular changes in the endocannabinoid system.

Published
2021
Full Text
View/download PDF

5. Beneficial Changes in Rat Vascular Endocannabinoid System in Primary Hypertension and under Treatment with Chronic Inhibition of Fatty Acid Amide Hydrolase by URB597.

Author

Baranowska-Kuczko M, Kozłowska H, Kloza M, Harasim-Symbor E, Biernacki M, Kasacka I, and Malinowska B

Subjects
Acetylcholine, Animals, Aorta, Arachidonic Acids, Hypertension metabolism, Male, Mesenteric Arteries drug effects, Nitroprusside, Polyunsaturated Alkamides, Rats, Rats, Inbred SHR, Rats, Inbred WKY, Receptors, Cannabinoid, Vasoconstriction, Vasodilation drug effects, Amidohydrolases drug effects, Amidohydrolases metabolism, Benzamides pharmacology, Carbamates pharmacology, Endocannabinoids metabolism, Essential Hypertension metabolism, Essential Hypertension therapy
Abstract

Our study aimed to examine the effects of hypertension and the chronic administration of the fatty acid amide hydrolase (FAAH) inhibitor URB597 on vascular function and the endocannabinoid system in spontaneously hypertensive rats (SHR). Functional studies were performed on small mesenteric G3 arteries (sMA) and aortas isolated from SHR and normotensive Wistar Kyoto rats (WKY) treated with URB597 (1 mg/kg; twice daily for 14 days). In the aortas and sMA of SHR, endocannabinoid levels and cannabinoid CB 1 receptor (CB 1 R) expression were elevated. The CB 1 R antagonist AM251 diminished the methanandamide-evoked relaxation only in the sMA of SHR and enhanced the vasoconstriction induced by phenylephrine and the thromboxane analog U46619 in sMA in SHR and WKY. In the sMA of SHR, URB597 elevated anandamide levels, improved the endothelium-dependent vasorelaxation to acetylcholine, and in the presence of AM251 reduced the vasoconstriction to phenylephrine and enhanced the vasodilatation to methanandamide, and tended to reduce hypertrophy. In the aortas, URB597 elevated endocannabinoid levels improved the endothelium-dependent vasorelaxation to acetylcholine and decreased CB 1 R expression. Our study showed that hypertension and chronic administration of URB597 caused local, resistance artery-specific beneficial alterations in the vascular endocannabinoid system, which may bring further advantages for therapeutic application of pharmacological inhibition of FAAH.

Published
2021
Full Text
View/download PDF

6. Reduction of the serotonin 5-HT 1B and 5-HT 2A receptor-mediated contraction of human pulmonary artery by the combined 5-HT 1B receptor antagonist and serotonin transporter inhibitor LY393558.

Author

Baranowska-Kuczko M, Kozłowska H, Schlicker E, Göthert M, MacLean MR, Kozłowski M, Kloza M, Sadowska O, and Malinowska B

Subjects
Aged, Benzamides pharmacology, Citalopram pharmacology, Female, Humans, Male, Middle Aged, Piperidones pharmacology, Pyridines pharmacology, Receptor, Serotonin, 5-HT1B, Receptor, Serotonin, 5-HT2A, Spiro Compounds pharmacology, Cyclic S-Oxides pharmacology, Pulmonary Artery drug effects, Serotonin 5-HT1 Receptor Antagonists pharmacology, Serotonin 5-HT2 Receptor Antagonists, Selective Serotonin Reuptake Inhibitors pharmacology, Thiadiazines pharmacology, Vasoconstriction drug effects
Abstract

Background: LY393558 is a combined antagonist of serotonin (5-HT) 5-HT 1B receptors and inhibitor of serotonin transporter (SERT). LY393558 reduces 5-HT-induced vasoconstriction and remodelling of rat and/or mouse pulmonary arteries. The aim of our study was to examine the effect of LY393558 on the 5-HT-stimulated vasoconstriction of human pulmonary arteries (hPAs) and to determine the underlying mechanism(s)., Methods: Vascular effects of 5-HT receptor agonists, antagonists and a SERT inhibitor were examined in organ bath studies on intralobar hPAs obtained from patients during resection of lung carcinoma., Results: Serotonin and agonists of the 5-HT 1B receptor (5-carboxamidotryptamine, 5-CT) and 5-HT 2A receptor (α-methyl-5-HT) contracted endothelium-intact hPAs in a concentration-dependent fashion. The 5-HT 1B antagonists SB224289 and GR55562 reduced responses induced by 5-HT and 5-CT and the 5-HT 2A antagonist ketanserin inhibited the effects of 5-HT and α-methyl-5-HT. Administration of the SERT inhibitor citalopram (at a concentration that failed to modify the 5-HT-induced vasoconstriction) in combination with SB224289 or GR55562 was more effective in inhibiting the response to 5-HT than the 5-HT 1B antagonists alone. LY393558 showed the greatest antagonistic effect against the vasoconstriction elicited by 5-HT, 5-CT and α-methyl-5-HT., Conclusions: LY393558 reduces the 5-HT-induced contraction antagonizing 5-HT 1B and 5-HT 2A receptors probably due to synergic interaction between SERT inhibition and 5-HT 1B receptor antagonism. Thus, it might represent a valuable future option in the pulmonary arterial hypertension therapy.

Published
2020
Full Text
View/download PDF

7. Vasodilatory effects of cannabidiol in human pulmonary and rat small mesenteric arteries: modification by hypertension and the potential pharmacological opportunities.

Author

Baranowska-Kuczko M, Kozłowska H, Kloza M, Sadowska O, Kozłowski M, Kusaczuk M, Kasacka I, and Malinowska B

Subjects
Aged, Animals, Blood Pressure drug effects, Desoxycorticosterone Acetate, Endothelium, Vascular drug effects, Endothelium, Vascular physiopathology, Female, Humans, Hypertension chemically induced, Male, Middle Aged, Rats, Rats, Inbred SHR, Antihypertensive Agents pharmacology, Cannabidiol pharmacology, Mesenteric Arteries drug effects, Pulmonary Artery drug effects, Vasodilation drug effects
Abstract

Objective: Cannabidiol (CBD) has been suggested as a potential antihypertensive drug. The aim of our study was to investigate its vasodilatory effect in isolated human pulmonary arteries (hPAs) and rat small mesenteric arteries (sMAs)., Methods: Vascular effects of CBD were examined in hPAs obtained from patients during resection of lung carcinoma and sMAs isolated from spontaneously hypertensive (SHR); 11-deoxycorticosterone acetate (DOCA-salt) hypertensive rats or their appropriate normotensive controls using organ bath and wire myography, respectively., Results: CBD induced almost full concentration-dependent vasorelaxation in hPAs and rat sMAs. In hPAs, it was insensitive to antagonists of CB1 (AM251) and CB2 (AM630) receptors but it was reduced by endothelium denudation, cyclooxygenase inhibitors (indomethacin and nimesulide), antagonists of prostanoid EP4 (L161982), IP (Cay10441), vanilloid TRPV1 (capsazepine) receptors and was less potent under KCl-induced tone and calcium-activated potassium channel (KCa) inhibitors (iberiotoxin, UCL1684 and TRAM-34) and in hypertensive, overweight and hypercholesteremic patients. The time-dependent effect of CBD was sensitive to the PPARγ receptor antagonist GW9662. In rats, the CBD potency was enhanced in DOCA-salt and attenuated in SHR. The CBD-induced relaxation was inhibited in SHR and DOCA-salt by AM251 and only in DOCA-salt by AM630 and endothelium denudation., Conclusion: The CBD-induced relaxation in hPAs that was reduced in hypertensive, obese and hypercholesteremic patients was endothelium-dependent and mediated via KCa and IP, EP4, TRPV1 receptors. The CBD effect in rats was CB1-sensitive and dependent on the hypertension model. Thus, modification of CBD-mediated responses in disease should be considered when CBD is used for therapeutic purposes.

Published
2020
Full Text
View/download PDF

8. Functional and structural changes in aorta of mice divergently selected for basal metabolic rate.

Author

Sawicka D, Maciak S, Kozłowska H, Kasacka I, Kloza M, Sadowska A, Sokołowska E, Konarzewski M, and Car H

Subjects
Animals, Basal Metabolism, Body Weight, Endothelium cytology, Endothelium metabolism, Male, Mice, Potassium Channels, Calcium-Activated metabolism, Aorta anatomy & histology, Aorta metabolism
Abstract

Cardiovascular diseases (CVD) are one of the most common causes of mortality likely genetically linked to the variation in basal metabolic rate (BMR). A robust test of the significance of such association may be provided by artificial selection experiments on animals selected for diversification of BMR. Here we asked whether genetically determined differences in BMR correlate with anatomical shift in endothelium structure and if so, the relaxation and contraction responses of the aorta in mice from two lines of Swiss-Webster laboratory mice (Mus musculus) divergently selected for high or low BMR (HBMR and LBMR lines, respectively). Functional and structural study of aorta showed that a selection for divergent BMR resulted in the between-line difference in diastolic aortic capacity. The relaxation was stronger in aorta of the HBMR mice, which may stem from greater flexibility of aorta mediated by higher activity of Ca 2+ -activated K + channels. Structural examination also indicated that HBMR mice had significantly thicker aorta's middle layer compared to LBMR animals. Such changes may promote arterial stiffness predisposing to cardiovascular diseases. BMR-related differences in the structure and relaxation ability of aortas in studied animals may be reminiscent of potential risk factors in the development of CVD in humans.

Published
2020
Full Text
View/download PDF

9. Modulation of Cardiovascular Function in Primary Hypertension in Rat by SKA-31, an Activator of K Ca 2.x and K Ca 3.1 Channels.

Author

Kloza M, Baranowska-Kuczko M, Toczek M, Kusaczuk M, Sadowska O, Kasacka I, and Kozłowska H

Subjects
Animals, Blood Pressure drug effects, Cardiovascular System physiopathology, Disease Models, Animal, Endothelium, Vascular metabolism, Essential Hypertension physiopathology, Rats, Rats, Inbred SHR, Benzothiazoles pharmacology, Cardiovascular System drug effects, Cardiovascular System metabolism, Essential Hypertension genetics, Essential Hypertension metabolism, Intermediate-Conductance Calcium-Activated Potassium Channels agonists, Small-Conductance Calcium-Activated Potassium Channels agonists
Abstract

The aim of this study was to investigate the hemodynamic effects of SKA-31, an activator of the small ( K Ca 2.x ) and intermediate ( K Ca 3.1 ) conductance calcium-activated potassium channels, and to evaluate its influence on endothelium-derived hyperpolarization (EDH)- K Ca 2.3 / K Ca 3.1 type relaxation in isolated endothelium-intact small mesenteric arteries (sMAs) from spontaneously hypertensive rats (SHRs). Functional in vivo and in vitro experiments were performed on SHRs or their normotensive controls, Wistar-Kyoto rats (WKY). SKA-31 (1, 3 and 10 mg/kg) caused a brief decrease in blood pressure and bradycardia in both SHR and WKY rats. In phenylephrine-pre-constricted sMAs of SHRs, SKA-31 (0.01-10 µM)-mediated relaxation was reduced and SKA-31 potentiated acetylcholine-evoked endothelium-dependent relaxation. Endothelium denudation and inhibition of nitric oxide synthase (eNOS) and cyclooxygenase (COX) by the respective inhibitors l -NAME or indomethacin, attenuated SKA-31-mediated vasorelaxation. The inhibition of K Ca 3.1 , K Ca 2.3 , K IR and Na + /K + -ATPase by TRAM-34, UCL1684, Ba 2+ and ouabain, respectively, reduced the potency and efficacy of the EDH-response evoked by SKA-31. The mRNA expression of eNOS, prostacyclin synthase, K Ca 2.3 , K Ca 3.1 and K IR were decreased, while Na + /K + -ATPase expression was increased. Collectively, SKA-31 promoted hypotension and vasodilatation, potentiated agonist-stimulated vasodilation, and maintained K Ca 2.3 / K Ca 3.1 -EDH-response in sMAs of SHR with downstream signaling that involved K IR and Na + /K + -ATPase channels. In view of the importance of the dysfunction of endothelium-mediated vasodilatation in the mechanism of hypertension, application of activators of K Ca 2.3 / K Ca 3.1 channels such as SKA-31 seem to be a promising avenue in pharmacotherapy of hypertension., Competing Interests: The authors declare that there are no conflicts of interest.

Published
2019
Full Text
View/download PDF

10. Nitric oxide as a modulator in platelet- and endothelium-dependent antithrombotic effect of eplerenone in diabetic rats.

Author

Gromotowicz-Poplawska A, Kloza M, Aleksiejczuk M, Marcinczyk N, Szemraj J, Kozlowska H, and Chabielska E

Subjects
Animals, Aorta drug effects, Aorta metabolism, Blood Platelets metabolism, Blood Pressure drug effects, Diabetes Mellitus, Experimental chemically induced, Diabetes Mellitus, Experimental metabolism, Endothelium, Vascular metabolism, Male, Mesenteric Arteries drug effects, Mesenteric Arteries metabolism, NG-Nitroarginine Methyl Ester pharmacology, Nitric Oxide Synthase Type III metabolism, Rats, Rats, Wistar, Streptozocin pharmacology, Vasodilation drug effects, Blood Platelets drug effects, Endothelium, Vascular drug effects, Eplerenone pharmacology, Fibrinolytic Agents pharmacology, Nitric Oxide pharmacology
Abstract

We have recently demonstrated the antithrombotic effect of eplerenone on the arterial thrombotic process in diabetic rats associated with suppression of coagulation and enhancement of fibrinolysis. The aim of this study was to evaluate the role of platelets and endothelium in the mechanism of eplerenone antithrombotic action. Diabetes was induced in male Wistar rats with a single injection of streptozotocin (65 mg/kg). On the 25 th day, treatment with eplerenone (100 mg/kg) was initiated for 10 days. Eplerenone did not change hemodynamic parameters (blood pressure, carotid blood flow, and heart rate), however, improved endothelium-dependent vasorelaxation in aortas and small mesenteric arteries, enhanced the aortic amounts of mRNA of endothelial nitric oxide synthase (eNOS), and reduced mRNA of nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) oxidase 2. A prolongation of bleeding time and decrease in platelet adhesion to collagen ex vivo was also observed. These changes were accompanied by prolonged time to occlusion and increased blood flow, and finally reduced thrombus mass in diabetic rats. The inhibition of NOS with L-NAME reduced the eplerenone antithrombotic effect. Our study provides evidence that the antithrombotic effect of eplerenone in diabetic rats is nitric oxide-dependent and associated with inhibiting the adhesion of platelets, as well as normalizing endothelial function. The mechanism of eplerenone antithrombotic action in diabetes is a result of improved endothelial nitric oxide bioavailability that leads to the improvement vascular and platelet function.

Published
2019
Full Text
View/download PDF

11. Endocannabinoids modulate G q/11 protein-coupled receptor agonist-induced vasoconstriction via a negative feedback mechanism.

Author

Karpińska O, Baranowska-Kuczko M, Kloza M, and Kozłowska H

Subjects
Angiotensin II metabolism, Animals, Antihypertensive Agents pharmacology, Arteries metabolism, Dinoprost metabolism, Feedback, Physiological, GTP-Binding Protein alpha Subunits, Gq-G11 drug effects, Humans, Ligands, Receptor Cross-Talk, Receptor, Cannabinoid, CB1 drug effects, Signal Transduction, Thromboxane A2 metabolism, Vasoconstrictor Agents pharmacology, Vasodilator Agents pharmacology, Arteries drug effects, Endocannabinoids metabolism, GTP-Binding Protein alpha Subunits, Gq-G11 metabolism, Receptor, Cannabinoid, CB1 metabolism, Vasoconstriction drug effects, Vasodilation drug effects
Abstract

Objectives: The endocannabinoid (eCB) system centrally and peripherally regulates cardiovascular parameters, including blood pressure, in health and disease. The relationship between G q/11 protein-coupled receptor activation, regulation of eCBs release (mainly 2-arachidonoylglycerol) and subsequent CB 1 receptor activation was initially observed in the central nervous system. Here, we review the latest findings from systemic physiological studies which include for the first time data from pulmonary arteries. We present evidence for direct CB 1 -dependent cannabinoid ligand-induced vasorelaxation, vascular expression of eCBs along with their degradation enzymes, and indicate the location of the described interaction., Key Findings: Endocannabinoids (mainly 2-arachidonoylglycerol), acting via CB 1 receptors, evoke vasodilatory effects and may modulate responses of vasoconstrictors for G q/11 protein-coupled receptors including angiotensin II, thromboxane A 2 , phenylephrine, noradrenaline in systemic or pulmonary arteries. However, the role of the endothelium in this interaction is not well-established, and the precise vascular location of eCB system components remains unclear, which contributes to discrepancies in the interpretation of results when describing the above-mentioned relationship., Summary: Endocannabinoid's negative feedback is responsible for diminishing agonist-induced vasoconstriction, which may be clinically important in the treatment of arterial and pulmonary hypertension. Further research is required to establish the importance of the eCB system and its downstream signalling pathways., (© 2017 Royal Pharmaceutical Society.)

Published
2018
Full Text
View/download PDF

12. Mechanisms of l-alpha-lysophosphatidylinositol-induced relaxation in human pulmonary arteries.

Author

Karpińska O, Baranowska-Kuczko M, Malinowska B, Kloza M, Kusaczuk M, Gęgotek A, Golec P, Kasacka I, and Kozłowska H

Subjects
Aged, Anilides pharmacology, Anisoles pharmacology, Azabicyclo Compounds pharmacology, Benzoates pharmacology, Bronchioles drug effects, Bronchioles metabolism, Cyclohexanes pharmacology, Dose-Response Relationship, Drug, Endothelium, Vascular drug effects, Enzyme Inhibitors pharmacology, Female, Humans, In Vitro Techniques, Male, Middle Aged, Muscle, Smooth, Vascular metabolism, NG-Nitroarginine Methyl Ester pharmacology, PPAR gamma antagonists & inhibitors, Potassium Channel Blockers pharmacology, Pulmonary Artery metabolism, Receptors, Cannabinoid, Receptors, G-Protein-Coupled antagonists & inhibitors, Receptors, G-Protein-Coupled biosynthesis, Receptors, G-Protein-Coupled genetics, Lysophospholipids pharmacology, Muscle Relaxation drug effects, Muscle, Smooth, Vascular drug effects, Pulmonary Artery drug effects
Abstract

Aims: l-Alpha-lysophosphatidylinositol (LPI) is an endogenous agonist of G protein-coupled receptor 55 (GPR55) which relaxes mesenteric arteries on activation. The aim of the present study was to determine the influence and underlying mechanisms of LPI-induced relaxation in human pulmonary arteries (hPAs)., Main Methods: Functional studies were performed in isolated hPAs using organ bath technique. The expression of GPR55 in hPAs and bronchioles was determined by real-time qPCR, Western blot analysis, and immunohistochemistry., Key Findings: LPI induced a concentration-dependent vasorelaxation in endothelium-intact hPAs. This effect was attenuated by the GPR55 antagonist CID16020046, the peroxisome proliferator-activated receptor-γ (PPARγ) antagonist GW9662, the putative endothelial cannabinoid receptor (CB e ) antagonist O-1918 and the inhibitor of nitric oxide (NO) synthase (L-NAME). In addition, vasorelaxation was also attenuated by the presence of a high KCl concentration, selective blockers of small (K Ca 2.3; UCL1684), intermediate (K Ca 3.1; TRAM-34) and large conductance (K Ca 1.1; iberiotoxin) calcium-activated potassium channels and by endothelium denudation. However, vasorelaxation was not attenuated by the cannabinoid CB 1 receptor antagonist AM251 or by the cyclooxygenase inhibitor indomethacin., Significance: The study showed that the LPI-induced vasorelaxation was endothelium-dependent and mediated by GPR55, PPARγ and CB e receptors, occurred in a NO- and calcium-activated potassium channel-dependent manner in isolated hPAs. LPI seems to possess positive, hypotensive properties in pulmonary vascular bed., (Copyright © 2017 Elsevier Inc. All rights reserved.)

Published
2018
Full Text
View/download PDF

13. The influence of DOCA-salt hypertension and chronic administration of the FAAH inhibitor URB597 on K Ca 2.3/K Ca 3.1-EDH-type relaxation in rat small mesenteric arteries.

Author

Kloza M, Baranowska-Kuczko M, Malinowska B, Karpińska O, Harasim-Symbor E, Kasacka I, and Kozłowska H

Subjects
Amidohydrolases metabolism, Animals, Desoxycorticosterone Acetate, Disease Models, Animal, Dose-Response Relationship, Drug, Hypertension enzymology, Hypertension etiology, Hypertension physiopathology, In Vitro Techniques, Male, Mesenteric Arteries enzymology, Mesenteric Arteries physiopathology, Rats, Wistar, Signal Transduction drug effects, Sodium Chloride, Dietary, Time Factors, Amidohydrolases antagonists & inhibitors, Antihypertensive Agents pharmacology, Benzamides pharmacology, Carbamates pharmacology, Enzyme Inhibitors pharmacology, Hypertension drug therapy, Intermediate-Conductance Calcium-Activated Potassium Channels metabolism, Mesenteric Arteries drug effects, Small-Conductance Calcium-Activated Potassium Channels metabolism, Vasodilation drug effects, Vasodilator Agents pharmacology
Abstract

The aim of this study was to examine the influence of deoxycorticosterone acetate-salt (DOCA-salt) hypertension and chronic treatment with the fatty acid amide hydrolase inhibitor, URB597, on small and intermediate conductance calcium-activated potassium channels and endothelium-dependent hyperpolarization (K Ca 2.3/K Ca 3.1-EDH) in rat small mesenteric arteries (sMAs). The EDH-type response was investigated, in endothelium-intact sMAs using a wire myograph, by examining acetylcholine-evoked vasorelaxation in the presence of N ω -nitro-L-arginine methyl ester and indomethacin (inhibitors of nitric oxide synthase and cyclooxygenase, respectively). In normo- and hypertension the efficacy of EDH-type relaxation was similar and inhibition of K Ca 2.3 and K Ca 3.1 by UCL1684 and TRAM-34, respectively, given alone or in combination, attenuated EDH-mediated vasorelaxation. K Ca 3.1 expression and NS309 (K Ca 2.3/K Ca 3.1 activator)-induced relaxation was reduced in sMAs of DOCA-salt rats. Endothelium denudation and incubation with UCL1684 and TRAM-34 attenuated the maximal NS309-evoked vasorelaxation in both groups. URB597 had no effect in functional studies, but increased the expression of K Ca 3.1 in the sMAs. K Ca 2.3/K Ca 3.1-EDH-mediated relaxation was maintained in the sMAs of DOCA-salt rats despite endothelial dysfunction and down-regulation of K Ca 3.1. Furthermore, K Ca 3.1 played a key role in the EDH-type dilator response of sMAs in normo- and hypertension. The hypotensive effect of URB597 is independent of K Ca 2.3/K Ca 3.1-EDH-type relaxation., (Copyright © 2017 Elsevier Inc. All rights reserved.)

Published
2017
Full Text
View/download PDF

14. Activation of CB 1 receptors by 2-arachidonoylglycerol attenuates vasoconstriction induced by U46619 and angiotensin II in human and rat pulmonary arteries.

Author

Karpińska O, Baranowska-Kuczko M, Kloza M, Ambroz Ewicz E, Kozłowski T, Kasacka I, Malinowska B, and Kozłowska H

Subjects
Aged, Animals, Cannabinoid Receptor Antagonists pharmacology, Dose-Response Relationship, Drug, Female, Humans, In Vitro Techniques, Male, Middle Aged, Pulmonary Artery metabolism, Rats, Wistar, Receptor, Cannabinoid, CB1 metabolism, Signal Transduction drug effects, 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid pharmacology, Angiotensin II pharmacology, Arachidonic Acids pharmacology, Cannabinoid Receptor Agonists pharmacology, Endocannabinoids pharmacology, Glycerides pharmacology, Pulmonary Artery drug effects, Receptor, Cannabinoid, CB1 agonists, Vasoconstriction drug effects, Vasoconstrictor Agents pharmacology, Vasodilation drug effects, Vasodilator Agents pharmacology
Abstract

Recent evidence suggests that endocannabinoids acting via cannabinoid CB 1 receptors may modulate vascular responses of various vasoconstrictors in the rodent systemic vasculature. The aim of the study was to investigate whether endocannabinoids modulate the contractile responses evoked by a thromboxane A 2 analog (U46619), angiotensin II (ANG II), serotonin (5-HT), and phenylephrine, which stimulate distinct G q/11 protein-coupled receptors (thromboxane, ANG II type 1, 5-HT 2 , and α 1 -adrenergic receptors) in isolated endothelium-intact human and rat pulmonary arteries (hPAs and rPAs, respectively). The CB 1 receptor antagonist AM251 (1 μM) and diacylglycerol lipase (2-arachidonoylglycerol synthesis enzyme) inhibitor RHC80267 (40 μM) enhanced contractions induced by U46619 in hPAs and rPAs and by ANG II in rPAs in an endothelium-dependent manner. AM251 did not influence vasoconstrictions induced by 5-HT or phenylephrine in rPAs. The monoacylglycerol lipase (2-arachidonoylglycerol degradation enzyme) inhibitor JZL184 (1 μM), but not the fatty acid amide hydrolase (anandamide degradation enzyme) inhibitor URB597 (1 μM), attenuated contractions evoked by U46619 in hPAs and rPAs and ANG II in rPAs. 2-Arachidonoylglycerol concentration-dependently induced relaxation of hPAs, which was inhibited by endothelium denudation or AM251 and enhanced by JZL184. Expression of CB 1 receptors was confirmed in hPAs and rPAs using Western blotting and immunohistochemistry. The present study shows the protective interaction between the endocannabinoid system and vasoconstriction in response to U46619 and ANG II in the human and rat pulmonary circulation. U46619 and ANG II may stimulate rapid endothelial release of endocannabinoids (mainly 2-arachidonoylglycerol), leading to CB 1 receptor-dependent and/or CB 1 receptor-independent vasorelaxation, which in the negative feedback mechanism reduces later agonist-induced vasoconstriction., (Copyright © 2017 the American Physiological Society.)

Published
2017
Full Text
View/download PDF

15. Protective role of cannabinoid CB1 receptors and vascular effects of chronic administration of FAAH inhibitor URB597 in DOCA-salt hypertensive rats.

Author

Baranowska-Kuczko M, Kozłowska H, Kloza M, Karpińska O, Toczek M, Harasim E, Kasacka I, and Malinowska B

Subjects
Animals, Aorta drug effects, Arachidonic Acids antagonists & inhibitors, Arachidonic Acids pharmacology, Capsaicin analogs & derivatives, Capsaicin pharmacology, Desoxycorticosterone Acetate, Dose-Response Relationship, Drug, Drug Interactions, Hypertension chemically induced, Male, Mesenteric Arteries drug effects, Morpholines pharmacology, Phenylephrine pharmacology, Pyrazoles pharmacology, Rats, Receptor, Cannabinoid, CB1 antagonists & inhibitors, Sodium Chloride, Vasoconstriction drug effects, Vasodilation drug effects, Amidohydrolases antagonists & inhibitors, Benzamides administration & dosage, Benzamides pharmacology, Blood Pressure physiology, Carbamates administration & dosage, Carbamates pharmacology, Hypertension physiopathology, Receptor, Cannabinoid, CB1 physiology
Abstract

Aims: This study examined whether the fall in blood pressure (BP) induced by the chronic inhibition of fatty acid amide hydrolase (FAAH) by URB597 in deoxycorticosterone acetate (DOCA-salt) hypertensive rats correlates with endocannabinoid-mediated vascular changes., Main Methods: Functional studies were performed in isolated endothelium-intact aortas and small mesenteric arteries (sMAs) using organ bath technique and wire myography, respectively., Key Findings: In the DOCA-salt rats, methanandamide-stimulated relaxation was enhanced in sMAs or diminished in aortas. Its vasorelaxant effect in sMAs was sensitive to the antagonist of the Transient Receptor Potential Vanilloid type 1 (TRPV1), capsazepine, in normo- and hypertensive animals and to the antagonist of the cannabinoid CB1 receptors, AM6545, only in DOCA-salt rats. Cannabinoid CB1 receptors were up-regulated merely in DOCA-salt sMAs. URB597 decreased elevated BP in DOCA-salt rats, medial hypertrophy in DOCA-salt aortas. In sMAs it reduced FAAH expression and restored the augmented phenylephrine-induced contraction in the DOCA-salt rats to the level obtained in normotensive controls. In normotensive rats it diminished endothelium-dependent relaxation and increased phenylephrine-induced contraction., Significance: The study showed the protective role of cannabinoid CB1 receptors in DOCA-salt sMAs. Reduction in BP after chronic administration of the FAAH inhibitor URB597 in DOCA-salt hypertensive rats only partially correlates with structural and functional changes in conductance and resistance vessels, respectively. Caution should be taken in studying cannabinoids and FAAH inhibitors as potential therapeutics, because of their vessel- and model-specific activities, and side effects connected with off-target response and activation of alternative pathways of anandamide metabolism., (Copyright © 2016 Elsevier Inc. All rights reserved.)

Published
2016
Full Text
View/download PDF

16. The adrenal medulla, not CB1 receptors, mediates the inhibitory effect of acute transverse aortic constriction on the neurogenic vasopressor response.

Author

Karabowicz P, Schlicker E, Pędzińska-Betiuk A, Kloza M, and Malinowska B

Subjects
Animals, Autonomic Fibers, Preganglionic drug effects, Electric Stimulation, Heart Rate drug effects, Male, Myocardial Contraction drug effects, Phenylephrine pharmacology, Rats, Rats, Wistar, Receptor, Cannabinoid, CB1 agonists, Receptor, Cannabinoid, CB1 antagonists & inhibitors, Vasopressins pharmacology, Adrenal Medulla pathology, Blood Pressure drug effects, Constriction, Pathologic pathology, Receptor, Cannabinoid, CB1 drug effects
Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results